使用单倍体相合孙辈供者及移植后环磷酰胺预防移植物抗宿主病的异基因血液或骨髓移植
本研究比较了55岁及以上接受异基因血液或骨髓移植的患者中,使用子女供者(C组,n=276)与孙辈供者(GC组,n=40)的安全性和有效性。结果显示,尽管GC组受者年龄更大且合并症更多,两组的2年总生存率、无复发生存率、非复发死亡率和复发率均无显著差异。作者认为,在为老年移植受者选择供者时,应考虑孙辈。
要点
- 孙辈供者组受者中位年龄73岁,子女供者组为67岁。
- 两组2年总生存率无显著差异(GC 62% vs C 60%)。
- 倾向性评分匹配后两组结局仍无显著差异。
核心结论
- 结果表明,尽管GC组受者年龄更大且合并症更多,但接受孙辈供者移植的alloBMT患者结局与接受子女供者移植者相似。
- 作者建议在为老年alloBMT受者选择供者时应考虑孙辈。
研究设计与样本
- 研究比较了年龄≥55岁接受alloBMT的患者,其中子女供者年龄>30岁为C组(n=276),孙辈供者为GC组(n=40)。
- 基于受者年龄、alloBMT年份、疾病、移植物来源和造血细胞移植合并症指数(HCT-CI)进行了倾向性评分匹配分析。
主要发现
- 受者中位年龄C组为67岁(范围55-79),GC组为73岁(范围57-78);GC组>70岁者超过70%,C组为27%。
- 供者中位年龄C组为37岁(范围31-52),GC组为20岁(范围14-34)。
- GC组HCT-CI评分≥3者占32.5%,C组占23%(p=0.27)。
- 2年总生存率GC组62% vs C组60%(HR 0.96,95%CI 0.53-1.75,p=0.90);2年无复发生存率C组55% vs GC组50%(HR 1.05,95%CI 0.62-1.77,p=0.85)。
- 非复发死亡(SDHR 1.36,95%CI 0.70-2.63,p=0.36)和复发(SDHR 0.72,95%CI 0.33-1.58,p=0.42)均无显著差异。
临床怎么用
- 作者认为,在为老年alloBMT受者选择供者时,应考虑孙辈。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: High-dose post-transplant cyclophosphamide allows safe and effective use of allografts from haploidentical relatives (siblings, parents and children) in patients undergoing allogeneic blood or marrow transplant (alloBMT). More recently, second- and third-degree relatives have also been shown to be safe allograft donors. An increasing number of older patients undergoing alloBMT have been receiving allografts from haploidentical donors. However, older patients are more likely to have older siblings and children, and older donor age is associated with worse outcomes. OBJECTIVE: In the current study, we report the safety and utility of grandchildren as haploidentical donors and compared with children as donors in patients undergoing alloBMT. METHODS: We compared characteristics and outcomes of alloBMT patients aged 55 years and older with children older than 30 years as donors (C group; n = 276) and those with grandchildren as donors (GC group; n = 40). Because many important baseline characteristics predict outcomes after alloBMT, we performed propensity score matched analysis based on recipient age, alloBMT year, disease, graft source and haematopoietic cell transplantation comorbidity index (HCT-CI). RESULTS: The median age of recipients was 67 years (range 55-79) in the C group and 73 years (range 57-78) in the GC group. More than 70% of recipients in the GC group were older than 70 years, compared with 27% in the C group. The median donor age was 37 years (range 31-52) in the C group and 20 years (range 14-34) in the GC group. More patients in the GC group had HCT-CI scores ≥3 than in the C group (32.5% vs. 23%, p = 0.27). Two-year overall survival did not differ between the two groups (GC 62% vs. C 60%, hazard ratio [HR] 0.96, 95% confidence interval [CI] 0.53-1.75, p = 0.90) despite recipients of allografts from grandchildren being older. The 2-year RFS was 55% in the C group compared with 50% in the GC group (HR 1.05, 95% CI 0.62-1.77, p = 0.85). Non-relapse mortality subdistribution [SD] (SDHR 1.36, 95% 0.70-2.63, p = 0.36), relapse (SDHR 0.72, 95% CI 0.33-1.58, p = 0.42) or relapse-free survival (HR 1.05, 95% CI 0.62-1.77, p = 0.85). Propensity score matching analysis showed no significant differences in 2-year overall survival (GC 64% vs. C 53%; HR 0.77, 95% CI 0.42-1.42, p = 0.40), non-relapse mortality (SDHR 1.26, 95% 0.66-2.41, p = 0.48), relapse (SDHR 0.57, 95% CI 0.21-1.52, p = 0.26) or relapse-free survival (HR 0.94, 95% CI 0.57-1.54, p = 0.81). CONCLUSION: Our results indicate that outcomes of alloBMT patients with grandchild donors are similar to those with child donors, despite recipients' older age and higher comorbidities in the GC group. Grandchildren should be considered when selecting a donor for older alloBMT recipients.
引用
- Aljawai YM, Tsai HL, Varadhan R, et al. Allogeneic blood or marrow transplantation using haploidentical grandchildren donors and post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis. Br J Haematol. 2024. PMID: 39099174. doi:10.1111/bjh.19673
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。